Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;3(1):32-40.
doi: 10.1177/1941738110386705.

Boosting The Late Blooming Male: Use of growth promoting agents in the athlete with constitutional delay of growth and puberty

Affiliations

Boosting The Late Blooming Male: Use of growth promoting agents in the athlete with constitutional delay of growth and puberty

Vanessa A Curtis et al. Sports Health. 2011 Jan.

Abstract

CONTEXT: The indications for use of growth hormone (GH) have broadened with the availability of unlimited recombinant human growth hormone (rhGH). The FDA's approval for use of growth hormone in GH-sufficient patients with idiopathic short stature includes some children with constitutional delay of growth and puberty (CGD), a normal growth pattern variation which includes delayed puberty and prolonged linear growth, usually leading to normal adult height. Use of rhGH to increase growth in short-statured children with CGD has been challenged for its modest efficacy in increasing ultimate height, high cost, limited evidence for psychosocial benefit, and some unresolved concerns about long-term post-treatment safety. An additional controversy for the young athlete with CGD is the concern for fairness in competition. EVIDENCE ACQUISITION: Data sources were limited to peer-reviewed publications. RESULTS: RhGH is a safe and effective therapy for increasing growth rate in very short children with CGD, but does not markedly increase ultimate stature nor confer a clear benefit in athletic performance. (SORT A) CONCLUSIONS: Prescribing physicians should use rhGH treatment responsibly to bring children disabled by short stature just into the "normal" range. (SORT C).

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest declared.

Figures

Figure 1.
Figure 1.
Evaluation of boys with delayed puberty. FH, family history; BUN, blood urea nitrogen; Cr, creatinine; TSH, thyroid-stimulating hormone; fT4, free tetraiodothyronine (thyroxine); IGF-1, insulin-like growth factor 1; ESR, erythrocyte sedimentation rate; LTs, liver tests; CGD, constitutional delay of growth and puberty; LH, luteinizing hormone; FSH, follicle-stimulating hormone; HH, hypogonadotropic hypogonadism; CNS, central nervous system.
Figure 2.
Figure 2.
Height velocity curve for males aged 2 to 20 years. Late maturer curve approximated for 2 standard deviation (± 2 SD) delay. From Tanner JM, Davis PSW. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317-329. Reprinted with permission.

Similar articles

Cited by

References

    1. Allen DB, Fost N. hGH for short stature: ethical issues raised by expanded access. J Pediatr. 2004;144(5):648-652 - PubMed
    1. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167-177 - PubMed
    1. Berggren A, Ehrnborg C, Rosen T, Ellegard L, Bengtsson BA, Caidahl K. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J Clin Endocrinol Metab. 2005;90(6):3268-3273 - PubMed
    1. Branski LK, Herndon DN, Barrow RE, et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children [published online ahead of print September 2, 2009]. Ann Surg. - PMC - PubMed
    1. Bryant J, Baxter L, Cave CB, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev. 2007;3:CD004440 - PubMed